Total Payments
$8,530
2023 Payments
$44.59
Companies
7
Transactions
16
Medicare Patients
17,321
Medicare Billing
$18.9M
Payment Breakdown by Category
Consulting$6,540 (76.7%)
Travel$1,008 (11.8%)
Food & Beverage$981.65 (11.5%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $6,540 | 3 | 76.7% |
| Travel and Lodging | $1,008 | 4 | 11.8% |
| Food and Beverage | $981.65 | 9 | 11.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Genentech USA, Inc. | $7,253 | 6 | $0 (2021) |
| Genentech, Inc. | $950.49 | 4 | $0 (2019) |
| Alimera Sciences, Inc. | $125.00 | 1 | $0 (2017) |
| Novartis Pharmaceuticals Corporation | $70.27 | 2 | $0 (2019) |
| Carl Zeiss Meditec, Inc. | $69.76 | 1 | $0 (2019) |
| Alcon Research LLC | $44.59 | 1 | $0 (2023) |
| Alcon Vision LLC | $16.04 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $44.59 | 1 | Alcon Research LLC ($44.59) |
| 2021 | $2,355 | 1 | Genentech USA, Inc. ($2,355) |
| 2020 | $2,371 | 2 | Genentech USA, Inc. ($2,355) |
| 2019 | $1,044 | 6 | Genentech, Inc. ($950.49) |
| 2018 | $2,590 | 5 | Genentech USA, Inc. ($2,543) |
| 2017 | $125.00 | 1 | Alimera Sciences, Inc. ($125.00) |
All Payment Transactions
16 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/06/2023 | Alcon Research LLC | Clareon (Device) | Food and Beverage | In-kind items and services | $44.59 | General |
| Category: Ophthalmology | ||||||
| 07/24/2021 | Genentech USA, Inc. | Lucentis (Biological) | Consulting Fee | Cash or cash equivalent | $2,355.00 | General |
| Category: Ophthalmology | ||||||
| 05/21/2020 | Genentech USA, Inc. | Lucentis (Biological) | Consulting Fee | Cash or cash equivalent | $2,355.00 | General |
| Category: Ophthalmology | ||||||
| 02/21/2020 | Alcon Vision LLC | ReSTOR (Device) | Food and Beverage | In-kind items and services | $16.04 | General |
| Category: Ophthalmology | ||||||
| 06/29/2019 | Genentech, Inc. | Non-Covered Product (Drug) | Food and Beverage | In-kind items and services | $239.85 | General |
| Category: None | ||||||
| 06/28/2019 | Genentech, Inc. | Non-Covered Product (Drug) | Travel and Lodging | In-kind items and services | $369.41 | General |
| Category: None | ||||||
| 06/28/2019 | Genentech, Inc. | Non-Covered Product (Drug) | Travel and Lodging | In-kind items and services | $224.87 | General |
| Category: None | ||||||
| 06/28/2019 | Genentech, Inc. | Non-Covered Product (Drug) | Food and Beverage | In-kind items and services | $116.36 | General |
| Category: None | ||||||
| 05/31/2019 | Carl Zeiss Meditec, Inc. | — | Food and Beverage | In-kind items and services | $69.76 | General |
| 04/04/2019 | Novartis Pharmaceuticals Corporation | BEOVU (Drug) | Food and Beverage | Cash or cash equivalent | $23.48 | General |
| Category: OPHTHALMOLOGY | ||||||
| 07/26/2018 | Novartis Pharmaceuticals Corporation | BROLUCIZUMAB (Drug) | Food and Beverage | In-kind items and services | $46.79 | General |
| 05/19/2018 | Genentech USA, Inc. | Lucentis (Biological) | Consulting Fee | Cash or cash equivalent | $1,830.00 | General |
| Category: Ophthalmology | ||||||
| 05/19/2018 | Genentech USA, Inc. | Lucentis (Biological) | Food and Beverage | In-kind items and services | $299.78 | General |
| Category: Ophthalmology | ||||||
| 05/19/2018 | Genentech USA, Inc. | Lucentis (Biological) | Travel and Lodging | In-kind items and services | $238.73 | General |
| Category: Ophthalmology | ||||||
| 05/19/2018 | Genentech USA, Inc. | Lucentis (Biological) | Travel and Lodging | In-kind items and services | $174.93 | General |
| Category: Ophthalmology | ||||||
| 11/11/2017 | Alimera Sciences, Inc. | Iluvien (Biological) | Food and Beverage | Cash or cash equivalent | $125.00 | General |
| Category: Ophthalmology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 16 | 4,137 | 48,037 | $21.6M | $4.8M |
| 2022 | 16 | 4,056 | 20,503 | $12.5M | $4.7M |
| 2021 | 15 | 4,290 | 19,123 | $8.2M | $4.9M |
| 2020 | 16 | 4,838 | 19,802 | $7.5M | $4.5M |
Total Patients
17,321
Total Services
107,465
Medicare Billing
$18.9M
Procedure Codes
63
All Medicare Procedures & Services
63 procedure records from CMS Medicare Utilization — Page 2 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 67108 | Repair of detached retina with drainage and removal of eye fluid between lens and retina | Facility | 2022 | 15 | 15 | $53,835 | $14,085 | 26.2% |
| 92004 | New patient complete exam of visual system | Office | 2022 | 117 | 117 | $54,405 | $12,290 | 22.6% |
| 67041 | Removal of membrane of retina | Facility | 2022 | 13 | 13 | $44,837 | $11,374 | 25.4% |
| 67042 | Removal of membrane of retina with removal of internal limiting membrane of retina | Facility | 2022 | 12 | 12 | $41,388 | $10,888 | 26.3% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2022 | 35 | 35 | $12,810 | $3,550 | 27.7% |
| 76512 | 2d ultrasound scan of eye tissue and structures | Office | 2022 | 24 | 35 | $5,472 | $1,406 | 25.7% |
| 92250 | Photography of the retina | Office | 2022 | 13 | 15 | $1,815 | $376.73 | 20.8% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2021 | 313 | 4,424 | $5.3M | $3.3M | 62.5% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2021 | 135 | 3,514 | $1.8M | $893,383 | 50.8% |
| 67028 | Injection of drug into eye | Office | 2021 | 656 | 3,297 | $495,485 | $329,728 | 66.5% |
| 92134 | Diagnostic imaging of retina | Office | 2021 | 1,321 | 4,316 | $179,573 | $131,026 | 73.0% |
| 92012 | Eye and medical examination for diagnosis and treatment, established patient | Office | 2021 | 703 | 1,260 | $115,323 | $82,447 | 71.5% |
| J9035 | Injection, bevacizumab, 10 mg | Office | 2021 | 271 | 1,332 | $200,520 | $76,975 | 38.4% |
| 92014 | Eye and medical examination for diagnosis and treatment, established patient, 1 or more visits | Office | 2021 | 532 | 619 | $80,012 | $54,175 | 67.7% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 163 | 163 | $27,003 | $19,809 | 73.4% |
| 67041 | Removal of membrane from the retina | Facility | 2021 | 20 | 20 | $21,265 | $15,887 | 74.7% |
| 92004 | Eye and medical examination for diagnosis and treatment, new patient, 1 or more visits | Office | 2021 | 70 | 70 | $10,862 | $7,763 | 71.5% |
| 92235 | Imaging of blood vessels in back of eye using fluorescein dye | Office | 2021 | 35 | 35 | $4,347 | $3,356 | 77.2% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 19 | 19 | $2,110 | $1,544 | 73.2% |
| 76512 | Ultrasound of eye disease, growth, or structure | Office | 2021 | 18 | 19 | $1,226 | $763.34 | 62.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 16 | 16 | $2,061 | $703.64 | 34.1% |
| 92250 | Photography of the retina | Office | 2021 | 18 | 19 | $753.35 | $477.73 | 63.4% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2020 | 269 | 3,616 | $4.3M | $2.7M | 62.4% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2020 | 135 | 3,888 | $1.9M | $1.0M | 53.5% |
| 67028 | Injection of drug into eye | Office | 2020 | 705 | 3,327 | $434,773 | $293,492 | 67.5% |
About Dr. David Parke, MD
Dr. David Parke, MD is a Internal Medicine healthcare provider based in Minneapolis, Minnesota. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/22/2007. The National Provider Identifier (NPI) number assigned to this provider is 1265638746.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Parke, MD has received a total of $8,530 in payments from pharmaceutical and medical device companies, with $44.59 received in 2023. These payments were reported across 16 transactions from 7 companies. The most common payment nature is "Consulting Fee" ($6,540).
As a Medicare-enrolled provider, Parke has provided services to 17,321 Medicare beneficiaries, totaling 107,465 services with total Medicare billing of $18.9M. Data is available for 4 years (2020–2023), covering 63 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Ophthalmology, Ophthalmology
- Location Minneapolis, MN
- Active Since 06/22/2007
- Last Updated 09/26/2013
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1265638746
Products in Payments
- Lucentis (Biological) $7,253
- Non-Covered Product (Drug) $950.49
- Iluvien (Biological) $125.00
- BROLUCIZUMAB (Drug) $46.79
- Clareon (Device) $44.59
- BEOVU (Drug) $23.48
- ReSTOR (Device) $16.04
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Minneapolis
Dr. Jay Cohn, M.d, M.D
Internal Medicine — Payments: $924,540
Internal Medicine $924,540
Dr. Nedaa Skeik, Md, MD
Internal Medicine — Payments: $669,804
Internal Medicine $669,804
Mark Reding, Md, MD
Internal Medicine — Payments: $607,358
Internal Medicine $607,358
Wesley Pedersen, Md, MD
Internal Medicine — Payments: $595,626
Internal Medicine $595,626
Shilpa Gupta, Md, Mbbs, MD, MBBS
Internal Medicine — Payments: $528,257
Internal Medicine $528,257
Dr. Marshall Hertz, M.d, M.D
Internal Medicine — Payments: $398,078
Internal Medicine $398,078